UCB and its design partners, OXO® and Smart Design, win 2009 "Red
Dot: Communication Design"
(Thomson Reuters ONE) - * Cimzia® (certolizumab pegol) packaging wins international "Red Dot" design award * Patient-centric approach drove innovation in Cimzia® packaging componentsBrussels (Belgium), August 12th, 2009 - UCB announced today that thenewly designed Cimzia® packaging was honoured with a "Red DotCommunication Design" award, given by a respected international juryfor the largest and most renowned global design competition, the "RedDot Award".The Red Dot Awards recognize the best in product design,communication design, and design concepts. This year theirCommunication Design competition received over 6000 entries from 42countries. Winners of this coveted award are evaluated according tocriteria such as degree of innovation, functionality and the formalquality."For Cimzia® in rheumatoid arthritis (RA), UCB developed premiumpackaging components that shift the paradigm of pharmaceuticalpackaging by designing for the consumer first. I am proud of thispatient-centric approach and the fact that people living withrheumatoid arthritis worked directly with the design teams to developthe Cimzia® packaging," said Roch Doliveux, CEO of UCB.UCB partnered with OXO Good Grips®, a company dedicated to Universal(or "inclusive") Design, to develop their new Cimzia® syringe andpackaging components. As OXO®'s long-time design partner, SmartDesign led the team in developing all the elements of the new Cimzia®packaging components (the syringe itself, the packaging and theaccompanying guides).Davin Stowell, CEO and founder of Smart Design, explains theapproach. "The design team immersed themselves in the world of peoplewho live with RA in order to really understand their experience withlimited dexterity. We developed a syringe and packaging componentsdesigned specifically for RA patients. We aimed to make patients feelmore in control during the process of self-injection, more empowered,instead of reminding them of their illness."Cimzia®'s friendly packaging not only aims to promote compliance butalso aims to provide a positive, caring user experience. A curvedfront panel allows fingers to slide under and lift it open. Followingthree easy steps, the design leads users through a thoughtful andstraightforward process. The tray accommodates a wide range ofpatients' dexterity limitations when removing the syringe. Theinformation hierarchy is clear and concise with a personal,conversational tone that is human and respectful.As part of the packaging components, a "step-by-step" guide extractskey information from the full Patient Information Leaflet. The guidefollows the same design as the box, and includes simple photographythat aims to communicate the features of the syringe at a quickglance, highlighting the ergonomic design and OXO® brandcollaboration.UCB, OXO® and Smart Design will receive the award at a gala awardsdinner in Essen, Germany on December 9, 2009.Further informationNancy Nackaerts, External Communications, UCBT +32.2.559.9264, nancy.nackaerts(at)ucb.comMercedes Coats, Marketing Communications Manager SMART DESIGNT +1415 355 6205, Mercedes.Coats(at)SmartDesignWorldwide.comGretchen Holt, Corporate Communications Manager OXO T +1212 242 3333, gholt(at)oxo.comNotes to EditorsAbout Cimzia®Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor).Cimzia® has a high affinity for human TNF-alpha, selectivelyneutralizing the pathophysiological effects of TNF-alpha. Over thepast decade, TNF-alpha has emerged as a major target of basicresearch and clinical investigation. This cytokine plays a key rolein mediating pathological inflammation, and excess TNF-alphaproduction has been directly implicated in a wide variety ofdiseases. The U.S. Food and Drug Administration (FDA) has approvedCimzia® for reducing signs and symptoms of Crohn's disease andmaintaining clinical response in adult patients with moderately toseverely active disease who have had an inadequate response toconventional therapy and for the treatment of adults with moderatelyto severely active rheumatoid arthritis. Cimzia® was approved inSwitzerland for induction of a clinical response and for themaintenance of a clinical response and a remission in patients withactive Crohn's disease who have not responded adequately toconventional treatment in September 2007. UCB is also developingCimzia® in other autoimmune disease indications. Cimzia® is aregistered trademark of UCB S.A.OXO® and GOOD GRIPS® are trademarks of Helen of Troy Limited (NASDAQHELE) and are used under license.Important safety informationThe most common adverse reactions belonged to the system organclasses Infections and infestations, reported in 15.5% of patients onCimzia and 7.6% of patients on placebo, and General disorders andadministration site conditions, reported in 10.0% of patients onCimzia and 9.7% of patients on placebo. The most serious adversereactions were serious infections (including tuberculosis andhistoplasmosis), malignancies (including lymphoma) and heart failure.A pooled analysis of the safety data show there was a low incidenceof injection site pain (1.5%) and low level of discontinuations dueto adverse events.Cimzia® is contraindicated in patients with active tuberculosis orother severe infections such as sepsis, abscesses and opportunisticinfections and in patients with moderate to severe heart failure.Before initiation of Cimzia®, evaluate patients for both active orinactive (latent) tuberculosis infection. Monitor patients for thedevelopment of signs and symptoms of infection during and aftertreatment with Cimzia®. If an infection develops, monitor carefully,and stop Cimzia® if infection becomes serious.Use of TNF blockers, including Cimzia®, may increase the risk ofreactivation of hepatitis B virus (HBV) in patients who are chroniccarriers of this virus, of new onset or exacerbation of clinicalsymptoms and/or radiographic evidence of demyelinating disease, inthe formation of autoantibodies and uncommonly in the development ofa lupus-like syndrome or of severe hypersensitivity reactionsfollowing Cimzia administration. If a patient develops any of theseadverse reactions, Cimzia® should be discontinued and appropriatetherapy instituted.Adverse reactions of the hematologic system, including medicallysignificant cytopenia, have been infrequently reported with Cimzia®.Advise all patients to seek immediate medical attention if theydevelop signs and symptoms suggestive of blood dyscrasias orinfection (e.g., persistent fever, bruising, bleeding, pallor) whileon Cimzia®. Consider discontinuation of Cimzia® therapy in patientswith confirmed significant haematological abnormalities.The use of Cimzia® in combination with biological DMARDS such asanakinra, abatacept and rituximab is not recommended due to apotential increased risk of serious infections. As no data areavailable, Cimzia® should not be administered concurrently with livevaccines or attenuated vaccines.Please see full prescribing information before prescribing.About UCBUCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical companydedicated to the research, development and commercialization ofinnovative medicines with a focus on the fields of central nervoussystem and immunology disorders. Employing approximately 10 000people in over 40 countries, UCB generated revenue of EUR 3.6 billionin 2008. UCB is listed on Euronext Brussels (symbol: UCB).About OXOFounded in 1990 on the concept of Universal Design, OXO's mission isto create consumer household products that ease the tasks of everydaylife for the widest range of users possible. Since the original 15items were introduced, the OXO collection has grown to more than 800strong covering areas for cooking, cleaning, gardening, storing,organizing and lighting. Today OXO Good Grips products are sold in 54countries and are included in the permanent collections of numerousmuseums. The company has won more than 100 design and business awardsworldwide. OXO is very frequently used as a case study on how awell-executed Universal Design philosophy can be a successfulbusiness strategy. OXO is owned by Helen of Troy Limited, a leadingdesigner, producer and global marketer of brand-name personal careand household consumer products.About Smart DesignSmart Design has been turning insight and innovation into successfulconsumer experiences for 30 years. As OXO's partner in designing theoriginal line of OXO Good Grips products, Smart Design wasinstrumental in bringing the principles of Universal Design to themass market. Their strategic approach brings together experts inproduct, brand, and interaction design, business factors,engineering, and design research to ensure that its solutions connectwith people. Smart Design's consistent results are delivered by a130-member international staff - working in teams across offices inNew York, San Francisco, and Barcelona. www.smartdesignworldwide.comAbout Red Dot Design AwardWith more than 11 000 submissions from 61 countries, theinternational "red dot design award" is the largest and most renowneddesign competition in the world. It is divided into the "Red DotAward: Product Design", the "Red Dot Award: Communication Design" andthe "Red Dot Award: Design Concept." The award-winning products areput before an international public in the red dot design museum. Eachyear an international jury reviews and evaluates the submittedproducts according to criteria such as degree of innovation,functionality and the formal quality. The group of jurors is made upof renowned designers and design experts from all over the world.Forward-looking statementsThis press release contains forward-looking statements based oncurrent plans, estimates and beliefs of management. Such statementsare subject to risks and uncertainties that may cause actual resultsto be materially different from those that may be implied by suchforward-looking statements contained in this press release. Importantfactors that could result in such differences include: changes ingeneral economic, business and competitive conditions, effects offuture judicial decisions, changes in regulation, exchange ratefluctuations and hiring and retention of its employees.This press release contains links to external websites that are outof UCB editorial control.For the pdf-version of this press release, please click on the linkbelow:http://hugin.info/133973/R/1334025/316476.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 12.08.2009 - 08:02 Uhr
Sprache: Deutsch
News-ID 4610
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 387 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"UCB and its design partners, OXO® and Smart Design, win 2009 "Red
Dot: Communication Design""
steht unter der journalistisch-redaktionellen Verantwortung von
UCB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
